Amgen (NASDAQ: AMGN) and Cytokinetics Incorporated (Nasdaq: CYTK) announced that data from the expansion phase of COSMIC-HF (Chronic Oral Study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Amgen (AMGN) Sees Double-Digit EPS Growth Out to 2018; UBS Raises Price target to $180 October 29, 2015 10:46 AM Roth Capital Maintains Cytokinetics (CYTJK) at 'Buy' Amid Encouraging COSMIC-HF DataOctober 27, 2015 2:52 PM Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart FailureOctober 27, 2015 8:00 AM